Lebanon, NHNCT07071038Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Lebanon, NH

Access cutting-edge breast cancer treatment through this clinical trial at a research site in Lebanon. Study-provided care at no cost to qualified participants.

Sponsored by Dartmouth-Hitchcock Medical Center

Quick Self-Assessment

See if you qualify for this Lebanon location

Preparing your pre-screening questions…

Expert Care in Lebanon

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Lebanon Location

Check if you qualify for this breast cancer clinical trial in Lebanon, NH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lebanon

    Convenient for NH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lebanon site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Lebanon

Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.

Sponsor: Dartmouth-Hitchcock Medical Center

Who Can Participate

Inclusion Criteria

Histologic documentation of DCIS or invasive breast cancer by core needle or incisional biopsy.
The DCIS or invasive cancer must be estrogen receptor alpha (ER)-positive
The invasive cancer must be HER2-negative (IHC 0-1+, or with a FISH ratio of \<1.8 if IHC is 2+ or if IHC has not been done)
Clinical Stage I-III invasive breast cancer or DCIS
Patients for whom adjuvant treatment with one of the following would be clinically indicated: letrozole, anastrozole, exemestane
Patients who anticipate continuing with adjuvant endocrine therapy for a minimum of 2 years at the time of registration
Women over 18 years of age who are post-menopausal, defined as last menstrual period \>2 years prior to registration, or \>1 year prior to registration with FSH and estradiol in post-menopausal range.
Patients must meet the following clinical laboratory criteria:
Absolute neutrophil count (ANC) \>1,000/mm3 and platelet count \> 75,000/mm3
Total bilirubin \<1.5 x the upper limit of the normal range (ULN).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 x ULN.
Ability to give informed consent.

Exclusion Criteria

Prior endocrine therapy for any histologically-confirmed cancer or prevention of breast cancer in the last 10 years is not allowed.
Any other adjuvant therapy for breast cancer. Exception: Bisphosphonate or denosumab treatment for metabolic bone issues are allowed.
Patients who are prescribed tamoxifen as the first endocrine therapy rather than an aromatase inhibitor.
Women who are pregnant or lactating.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lebanon?

Yes, this clinical trial (NCT07071038) has an active research site in Lebanon, NH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Lebanon, NH

If you're searching for breast cancer treatment options in Lebanon, NH, this clinical trial (NCT07071038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lebanon research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Lebanon, NH

See all breast cancer clinical trials recruiting in Lebanon — not just this study.

Browse Breast Cancer Trials in Lebanon →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Lebanon?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lebanon, NH